目的 分析坤復(fù)康片聯(lián)合司帕沙星治療慢性盆腔炎的臨床效果。方法 選擇2017年2月-2019年3月在南陽市臥龍區(qū)第一人民醫(yī)院治療的慢性盆腔炎患者179例，隨機(jī)分為對(duì)照組（89例）和治療組（90例）。對(duì)照組患者口服司帕沙星片，0.1 g/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服坤復(fù)康片，3~4片/次，3次/d。兩組患者連續(xù)治療1個(gè)月。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者白細(xì)胞介素-2（IL-2）、腫瘤壞死因子-α（TNF-α）和C反應(yīng)蛋白（CRP）水平，及臨床癥狀改善時(shí)間。結(jié)果 治療后，對(duì)照組臨床有效率為77.53%，顯著低于治療組的94.44%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者IL-2明顯升高（P<0.05），而TNF-α和CRP水平顯著降低（P<0.05），且治療組患者IL-2、TNF-α和CRP水平改善效果明顯優(yōu)于對(duì)照組（P<0.05）。治療后，治療組患者宮頸舉痛改善時(shí)間和小腹墜痛改善時(shí)間明顯比對(duì)照組短，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 坤復(fù)康片聯(lián)合司帕沙星治療慢性盆腔炎，可快速緩解患者宮頸舉痛改善時(shí)間和小腹墜痛等臨床癥狀，臨床療效較好，安全可靠。

Objective To analyze the clinical effect of Kunfukang Tablets combined with sparfloxacin in treatment of chronic pelvic inflammation. Methods Patients (179 cases) with chronic pelvic inflammation in the First People's Hospital of Nanyang Wolong District from February 2017 to March 2019 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were po administered with Sparfloxacin Tablets, 0.1 mg/time, once daily. Patients in the treatment group were po administered with Kunfukang Tablets on the basis of the control group, 3-4 tablets/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the IL-2, TNF-α, and CRP levels, and the improvement time of clinical symptoms in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 77.53%, which was significantly lower than 94.44% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the IL-2 levels in two groups were significantly increased (P < 0.05), but the TNF-α and CRP levels were significantly decreased (P < 0.05), and the IL-2, TNF-α and CRP levels in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the improvement time of cervical lifting pain and abdominal dropping pain in the treatment group was significantly shorter than that in the control group, and the difference was statistically significant between two groups (P < 0.05). Conclusion Kunfukang Tablets combined with sparfloxacin in treatment of chronic pelvic inflammation can rapidly relieve clinical symptoms such as cervical lifting pain and lower abdomen falling pain, which has better clinical efficacy with high safety and reliability.

R984